Q-omics provides the consensus-scored RUNX1T1 profile across patient tissues and cancer cell-line models. RUNX1T1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, RUNX1T1 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, RUNX1T1 RNA expression shows 24,745 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight UVM, THCA, and BRCA as cancer lineages where RUNX1T1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RUNX1T1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RUNX1T1 survival associations across molecular data types. RUNX1T1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (9) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RUNX1T1 RNA expression–survival associations across cancer types. High RUNX1T1 expression shows unfavorable associations in UVM and KIRP, but favorable associations in HNSC, LGG, KIRC and UCS. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for RUNX1T1 RNA expression.
This table summarizes RUNX1T1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RUNX1T1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RUNX1T1 shows lower tumor expression in THCA, KIRP, BLCA, LUSC, KICH and LUAD. The THCA box plot shows higher RUNX1T1 RNA expression in normal versus tumor tissue (log2 FC = −1.375, t-test p < 0.001).
This table shows molecular features associated with RUNX1T1 in patient tissues and cancer cell lines. In patient samples, RUNX1T1 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, RUNX1T1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
